1. Home
  2. JYNT vs LCTX Comparison

JYNT vs LCTX Comparison

Compare JYNT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.54

Market Cap

117.7M

Sector

Miscellaneous

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.01

Market Cap

255.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
LCTX
Founded
2010
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.7M
255.4M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
JYNT
LCTX
Price
$8.54
$1.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$17.00
$6.25
AVG Volume (30 Days)
74.0K
978.6K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
133.93
N/A
EPS
0.14
N/A
Revenue
$117,696,356.00
$14,556,000.00
Revenue This Year
$12.23
$109.40
Revenue Next Year
N/A
N/A
P/E Ratio
$60.00
N/A
Revenue Growth
15.49
53.24
52 Week Low
$7.50
$1.00
52 Week High
$10.67
$2.09

Technical Indicators

Market Signals
Indicator
JYNT
LCTX
Relative Strength Index (RSI) 54.74 39.23
Support Level $8.44 N/A
Resistance Level $8.65 $1.18
Average True Range (ATR) 0.25 0.05
MACD 0.04 -0.00
Stochastic Oscillator 82.02 6.25

Price Performance

Historical Comparison
JYNT
LCTX

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: